BioSpace News Archive

Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the first customer shipments of Revio long-read sequencing systems will commence on March 8, 2023.

Rapport Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of precision medicines for neurological disorders, launched with a $100 million Series A financing from Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation – JJDC, Inc.

Acorda Therapeutics, Inc. announced that Esteve Pharmaceuticals, S.A. has launched INBRIJA 33 mg in Spain.

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2022.

Enanta Pharmaceuticals, Inc . today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 10:00 a.m. ET.

CareDx, Inc. announced the issuance of a new position statement by the American Society of Transplant Surgeons supporting the use of CareDx’s AlloSure® Kidney for organ transplant surveillance, and AlloSure Heart and AlloMap® Heart.

Orthofix Medical Inc. announced Fitbone™ TAA intramedullary limb-lengthening system has passed 5,000 devices implanted to date with more than 20 years of clinical history demonstrating safety and effectiveness in limb lengthening and deformity correction in adults and children.

Small Pharma Inc. today announces further positive results from the Company’s Phase IIa trial of SPL026, the first placebo-controlled study of a short-duration psychedelic for the treatment of Major Depressive Disorder (“MDD”).

Dyne Therapeutics, Inc.today announced that management is scheduled to participate in virtual fireside chats at the following investor conferences.